Eli Lilly
Eli Lilly was an American pharmacist, pharmaceutical chemist, Union Army officer, businessman, and philanthropist who founded Eli Lilly and Company in Indianapolis in 1876.
Last updated November 16, 2026
AI crawler reads
78requests
6AI- OpenAI27
- Perplexity20
- Amazon16
- Anthropic10
- Shape3
- +12
- Profile
- 29
- Controversies
- 22
- JSON · MD
- 0
- First read
- Oct 29, 2026
- Latest read
- Nov 17, 2026
From this site's server log
Overview
Eli Lilly was an American pharmacist, pharmaceutical chemist, businessman, philanthropist, and Union Army officer whose name became associated with one of the United States' major pharmaceutical companies. Born in Baltimore, Maryland, on July 8, 1838, he grew up in Kentucky and Indiana before developing an interest in pharmacy during his adolescence. In 1854, while visiting Lafayette, Indiana, he observed pharmacist Henry Lawrence preparing medicines at the Good Samaritan Drug Store. Lilly subsequently completed a four-year apprenticeship under Lawrence, learning both pharmaceutical compounding and the practical disciplines of accounting, purchasing, and business management. Lilly's early professional life included work in retail and wholesale pharmacies in Lafayette, Indianapolis, and Greencastle. He opened a drugstore in Greencastle in January 1861, but the Civil War soon redirected his career. He served in the Union Army, first with the 21st Indiana Infantry, and later organized and commanded the 18th Independent Battery Indiana Light Artillery, commonly known as the Lilly Battery. His unit fought in several campaigns and battles in the western theater, including Hoover's Gap, Chattanooga, Chickamauga, and Mossy Creek. In 1864 he joined the 9th Indiana Cavalry, attained the rank of major and later colonel, and was captured during the Battle of Sulphur Creek Trestle in Alabama. He remained a Confederate prisoner until January 1865 and was mustered out later that year. After the war, Lilly attempted to operate a cotton plantation in Mississippi. The venture failed after disease affected his family, his first wife Emily died in 1866, the crop suffered from drought, and his business partner disappeared with remaining funds. Lilly returned to the pharmaceutical trade, worked for wholesale drug firms, and later operated a pharmacy in Paris, Illinois. In 1873 he returned to Indianapolis and entered a drug-manufacturing partnership with John F. Johnston. After that partnership ended, Lilly established his own pharmaceutical manufacturing business on May 10, 1876, in a rented two-story building on West Pearl Street. The enterprise began with three employees, including his fourteen-year-old son Josiah K. Lilly Sr., and modest working capital. Lilly distinguished his business from many nineteenth-century patent-medicine sellers by emphasizing standardized production, prescription-oriented distribution, and product quality. His early manufacturing innovations included gelatin-coated pills and capsules, fruit flavorings, and sugar-coated medicines designed to make treatments easier to take. He also introduced more systematic controls over ingredients, dosage, production, and packaging. His early commercial success came from products including quinine and Succus Alterans, although the latter was marketed using therapeutic claims and a secret formula that reflected the limitations of nineteenth-century pharmaceutical science. The profits generated by these products helped fund the company's later investment in research and manufacturing modernization. A notable feature of Lilly's business was its early commitment to dedicated scientific and quality personnel. In 1886 he hired Ernest G. Eberhardt as a full-time research chemist and Walter H. Evans as a botanist. Lilly sought to improve the reliability and consistency of medicines at a time when adulteration, inconsistent formulations, and exaggerated therapeutic claims were widespread. He also supported the emerging practice of restricting potentially dangerous or addictive medicines to patients who had consulted physicians. His approach helped establish principles that later became central to modern pharmaceutical manufacturing and regulation. Around 1890, Lilly transferred day-to-day management of the company to his son, Josiah K. Lilly Sr., allowing him to devote more time to civic and charitable work. Eli Lilly remained connected to the business and to Indianapolis public life until his death from cancer on June 6, 1898. His legacy continued through the company, the later leadership of his descendants, and the philanthropic activities of the Lilly family, including the Lilly Endowment established in 1937 by his son and grandsons. The subject of this dossier is the historical individual Eli Lilly, not the modern pharmaceutical corporation, which has a separate corporate identity and Wikipedia article.
History
Eli Lilly was born on July 8, 1838, in Baltimore, Maryland, as the first of eleven children of Gustavus and Esther Lilly. His family moved during his childhood, eventually settling near Greencastle, Indiana. He attended Indiana Asbury University, later renamed DePauw University, from 1852 to 1854, and briefly worked at a printing press. His interest in chemistry developed when he visited the Good Samaritan Drug Store in Lafayette at age sixteen. The proprietor, Henry Lawrence, accepted him as an apprentice and trained him in pharmaceutical preparation as well as the commercial operation of a drugstore. After completing his apprenticeship, Lilly worked for druggists in Lafayette and Indianapolis. In 1860 he returned to Greencastle, where he worked in a local drugstore and soon opened a business of his own. His civilian career was interrupted by the American Civil War. Lilly initially enlisted in the Union Army in 1861, then returned to Indiana to recruit and organize the 18th Independent Battery Indiana Light Artillery. Although young and relatively inexperienced, he became an effective artillery commander. The battery served under John T. Wilder's Lightning Brigade and participated in campaigns in Kentucky and Tennessee, including the battles of Hoover's Gap, Chattanooga, Chickamauga, and Mossy Creek. In 1864 Lilly joined the 9th Indiana Cavalry and was promoted to major. He was captured by Confederate forces at Sulphur Creek Trestle in Alabama in September of that year and held at a prisoner-of-war camp in Enterprise, Mississippi. He was released in a prisoner exchange in January 1865, later received promotion to colonel, and left military service after the war. The title Colonel remained part of his public identity for the rest of his life. Lilly's first postwar business venture was an attempt to operate a large cotton plantation in Mississippi. The enterprise collapsed after illness spread through the household, his first wife Emily died while pregnant, drought damaged the crop, and Lilly's partner disappeared with company funds. Lilly returned to Indiana and worked for wholesale drug companies before moving to Paris, Illinois, where he opened the Red Front Drugstore with James W. Binford in 1869. He married Maria Cynthia Sloan later that year. Their daughter Eleanor was born in 1871 but died of diphtheria in 1884. In 1873 Lilly left the Illinois partnership and returned to Indianapolis. On January 1, 1874, he and John F. Johnston began a drug-manufacturing enterprise called Johnston and Lilly. When that partnership dissolved in 1876, Lilly used his remaining merchandise, equipment, and cash to establish an independent laboratory. On May 10, 1876, he opened Eli Lilly, Chemist, in a rented building at 15 West Pearl Street. His initial staff consisted of Albert Hall, Caroline Kruger, and his son Josiah, who worked as an apprentice. The new company manufactured medicines for wholesale distribution to pharmacies. Lilly's experience with inconsistent and sometimes ineffective medicines convinced him that pharmaceutical products should be made according to repeatable formulas and subject to systematic quality controls. He developed gelatin-coated pills and capsules, fruit-flavored preparations, and sugar-coated medicines. These changes improved the usability and consistency of medicines and helped the young company compete with patent-medicine sellers whose products were frequently promoted through extravagant claims. The business expanded quickly. Lilly hired his brother James as a full-time salesman in 1878, enabling the firm to reach customers outside Indiana. The company moved from Pearl Street to larger Indianapolis premises and was formally incorporated as Eli Lilly and Company in 1881. It also began building a more permanent research capability. In 1886, Lilly hired Ernest G. Eberhardt as its first full-time research chemist and Walter H. Evans as a botanist. This emphasis on scientific staff, manufacturing standards, and product testing became a defining part of the company's later identity. Lilly also participated in the development of emerging pharmaceutical ethics and regulation. He advocated for federal oversight of medicines and supported the idea that dangerous or addictive treatments should be dispensed only after medical consultation. These positions anticipated reforms associated with the 1906 federal food and drug legislation, although the modern Food and Drug Administration developed through later institutional changes. Around 1890, Eli Lilly transferred operational control to his son Josiah K. Lilly Sr. and devoted more time to civic and charitable activities. He helped establish the Commercial Club of Indianapolis, an antecedent of the Indianapolis Chamber of Commerce, supported charitable-organization work, and personally funded Eleanor Hospital. He also served in veterans' organizations and chaired the Grand Army of the Republic in Indiana in 1893. Lilly died in Indianapolis on June 6, 1898, after developing cancer. His descendants continued to shape the company and later established the Lilly Endowment, extending his commercial and philanthropic legacy beyond his lifetime.
- 1898
Death in Indianapolis
[1]Eli Lilly died of cancer in Indianapolis on June 6, 1898, at the age of fifty-nine.
- 1893
Leads Indiana veterans' organization
[1]Lilly served as chairman of the Grand Army of the Republic in Indiana and helped organize a large Union veterans' reunion and parade in Indianapolis.
- 1890
Transfers operating management to his son
[2]Eli Lilly turned day-to-day management of the company over to Josiah K. Lilly Sr. while increasing his civic and philanthropic activities.
- 1886
Creates a dedicated research function
[4]Lilly hired Ernest G. Eberhardt as a full-time research chemist and Walter H. Evans as a botanist, strengthening the company's scientific and quality-assurance capabilities.
- 1881
Company incorporation
[2]The business was formally incorporated as Eli Lilly and Company, with a board of directors and shares issued to family members and close associates.
- 1878
Begins national sales expansion
[2]Lilly hired his brother James as the company's first full-time salesman, helping extend distribution beyond Indiana.
- 1876
Founds Eli Lilly, Chemist
[3]On May 10, 1876, Lilly opened his independent pharmaceutical laboratory at 15 West Pearl Street in Indianapolis.
- 1874
Forms Johnston and Lilly
[2]Lilly and John F. Johnston established a drug-manufacturing operation in Indianapolis.
- 1869
Returns to the pharmaceutical trade
[1]After the failure of his Mississippi plantation venture, Lilly worked for drug wholesalers and opened the Red Front Drugstore in Paris, Illinois, with James W. Binford.
- 1864
Captured at Sulphur Creek Trestle
[1]While serving with the 9th Indiana Cavalry, Lilly was captured by Confederate forces in Alabama and held as a prisoner of war until January 1865.
Products and positioning
Historical pharmaceutical founder associated with scientific rigor, standardized drug manufacture, prescription-based distribution, quality assurance, and civic philanthropy.
Controversies
2026
Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicity
A patient has filed a lawsuit against Eli Lilly, alleging stomach problems that the patient ties to the medications Mounjaro and Trulicity, as reported by The Indiana Lawyer. The event was reported on October 8, 2026. The lawsuit concerns the patient's claim of stomach problems associated with the two medications. No further details regarding the outcome or additional allegations are provided in the source.
Brand decisions
2023
Eli Lilly to acquire remaining Sigilon sharesM&ABackground
Eli Lilly announced that it would acquire the Sigilon Therapeutics shares it does not already own for $14.92 per share, or $34.6 million in cash. The deal was expected to close in the third quarter of 2023.
2023
Eli Lilly agrees to acquire DiceM&ABackground
Eli Lilly announced that it had agreed to buy Dice, a biotechnology firm specializing in oral treatments for autoimmune diseases, for $2.4 billion.
2020
Eli Lilly announces plan to acquire DermiraM&ABackground
Eli Lilly announced that it would acquire Dermira for $1.1 billion. The article reports the announcement as having come on Friday.
2020
Eli Lilly announced an agreement to acquire Prevail TherapeuticsM&ABackground
Eli Lilly announced it would acquire Prevail Therapeutics for about $1 billion. Under the agreement, Prevail shareholders would receive $22.50 per share, including a contingent value right tied to regulatory approval of a product in development.
Recent events
Seawolf launches with $100 million in funding[28]
Reported
Seawolf Therapeutics launched publicly with $100 million in funding. The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics and others.
- Unconfirmed
LifeMD finalizes branded GLP-1 fulfillment arrangements with Eli Lilly and Novo Nordisk[29]
Reported
LifeMD finalized arrangements with Eli Lilly and Novo Nordisk to fulfill and ship their branded GLP-1 medications through LifeMD's pharmacy. Management said this could add revenue and gross profit dollars from prescriptions previously fulfilled through third parties.
- Unconfirmed
Former Eli Lilly representative sues over alleged Mounjaro marketing[13]
Reported
Former Eli Lilly sales representative Jennifer Mansion sued the company, alleging retaliation after she objected to Lilly's alleged promotion of Mounjaro for weight loss, a use described in the complaint as not approved at the time. The retaliation charge remains an allegation, not an established court finding.
- Unconfirmed
PHI Health sues employers over arbitration awards[30]
Reported
PHI Health has sued hundreds of employers to collect unpaid arbitration awards under the federal No Surprises Act. The article says the employer cases are still pending.
Eli Lilly raises its 2026 revenue outlook[31]
Reported
Eli Lilly raised its expected 2026 revenue range to $91 billion–$92 billion, from its previous guidance of $85 billion–$87 billion.
METiS TechBio and Eli Lilly announce drug-delivery partnership[32]
Reported
METiS TechBio and Eli Lilly announced a partnership to develop lipid nanoparticle-based delivery solutions, combining METiS's AI-driven lipid design with Lilly's drug discovery, development, and commercialization expertise. The deal is worth up to approximately $1.1 billion in potential milestone payments, in addition to an upfront payment and potential royalties.
- Unconfirmed
Eli Lilly weight-loss pill receives EU regulator backing[33]
Reported
Reuters reports that Eli Lilly's weight-loss pill received backing from an EU drug regulator; the headline does not specify the date or details of the backing.
- Unconfirmed
Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicity[11]
Reported
A patient has filed a lawsuit against Eli Lilly, alleging stomach problems that the patient ties to the medications Mounjaro and Trulicity, as reported by The Indiana Lawyer.
- Unconfirmed
Eli Lilly reports Phase 2 results showing eloralintide plus tirzepatide produced substantially more weight loss[34]
Reported
Eli Lilly reported Phase 2 trial data showing that its experimental amylin-targeting drug eloralintide, when combined with tirzepatide (the active ingredient in its Zepbound and Mounjaro shots), produced substantially more weight loss in patients with obesity and Type 2 diabetes. At 48 weeks, the highest-dose combination group lost an average of 23.3% of body weight versus 14.8% on a high dose of tirzepatide alone. More patients on the combination discontinued treatment due to side effects (10.8% to 27% depending on dose) than on tirzepatide alone (2.9%), and Lilly needs to confirm the results in Phase 3 trials that will begin later this year.
Eli Lilly breaks ground on $6.5 billion Houston manufacturing facility to ramp up Foundayo production[35]
Reported
Eli Lilly broke ground on its planned $6.5 billion manufacturing facility at Generation Park in Houston, Texas, which the company expects to be operational by 2030 and which will produce ingredients for the Foundayo obesity pill and other small-molecule medicines.
Sources94 sources
- 1Eli Lillyen.wikipedia.org
- 2Eli Lilly and Companyen.wikipedia.org
- 3History: Milestones of Caring and Discoverylilly.com
- 4Lilly timeline and therapeutic areasinvestor.lilly.com
- 5The Pharmaceutical Industry in Indianaindianahistory.org
- 6Eli Lilly and Company marks 140 years of caring and discoveryinvestor.lilly.com
- 7Eli Lilly to acquire remaining Sigilon sharesnews.cnyes.com
- 8Eli Lilly agrees to acquire Dicethedailyupside.com
- 9Eli Lilly announces plan to acquire Dermiramedcitynews.com
- 10Eli Lilly announced an agreement to acquire Prevail Therapeuticschinatimes.com
- 11Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityinsideindianabusiness.com
- 12Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityhealio.com
- 13Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityeconotimes.com
- 14Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityyahoo.com
- 15Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicitythedailyrecord.com
- 16Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityyahoo.com
- 17Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicitytheepochtimes.com
- 18Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicitycnbc.com
- 19Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicitymedscape.com
- 20Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityyahoo.com
- 21Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicitynbcnews.com
- 22Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicitydailymail.com
- 23Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityideastream.org
- 24Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityfinancialpost.com
- 25Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicitydailymail.com
- 26Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityyahoo.com
- 27Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicityklvi.iheart.com
- 28Seawolf 获得 1 亿美元融资并公开启动ksevradio.com
- 29LifeMD与礼来和诺和诺德敲定品牌GLP-1药物履约安排themarketsdaily.com
- 30PHI Health因仲裁裁决起诉雇主medicaldaily.com
- 31礼来上调2026年营收展望cnbc.com
- 32METiS TechBio与礼来宣布药物递送合作bioxconomy.com
- 33礼来减重药丸获得欧盟监管机构支持news.google.com
- 34礼来公布II期试验结果:eloralintide联合替尔泊肽减重效果更显著cnbc.com
- 35礼来为65亿美元休斯敦制造工厂动工以扩大Foundayo产量cnbc.com
- 36礼来在英国推出口服减肥药Foundayorte.ie
- 37Illumina推出Billion Cell Atlasfinanznachrichten.de
- 38Firefly Bio 融资 9,400 万美元并结束隐身状态medcitynews.com
- 39FDA批准礼来肥胖症治疗药物baystreet.ca
- 40Nido Biosciences获得1.09亿美元融资fiercebiotech.com
- 41Roche 与 Lilly 合作验证阿尔茨海默病血液检测geo.tv
- 42礼来扩大每月35美元胰岛素费用上限计划abcnews.com
- 43礼来宣布计划下调胰岛素价格delawarepublic.org
- 44FDA批准礼来Jaypirca用于治疗一种罕见血癌financialpost.com
- 45FDA加速批准Jaypircahealio.com
- 46FDA批准REZVOGLAR作为可互换生物类似药legal500.com
- 47保宁取得 Alimta 在韩国的销售权koreaherald.com
- 48FDA批准Olumiant用于治疗斑秃nbcdfw.com
- 49礼来宣布约 7 亿美元设施投资pmlive.com
- 50Eli Lilly宣布计划将胰岛素价格下调40%wibc.com
- 51FDA批准Lyumjev用于胰岛素泵medscape.com
- 52礼来与MiNA Therapeutics达成研究合作pmlive.com
- 53礼来与Biolojic合作开发糖尿病抗体疗法finance.sina.com.cn
- 54Eli Lilly任命Anat Ashkenazi为首席财务官southbendtribune.com
- 55礼来首席财务官乔什·斯迈利辞职dailymail.com
- 56礼来合作设立印第安纳州新冠输注中心wfyi.org
- 57FDA批准Eli Lilly新冠抗体疗法紧急使用wibc.com
- 58保宁制药取得 Gemzar 在韩国的权利koreaherald.com
- 59礼来中国与1药网合作开展糖尿病患者管理donews.com
- 60Lilly 与印第安纳州卫生部门合作开展新冠检测pmlive.com
- 61礼来推出偏头痛药物 Reyvowpmlive.com
- 62礼来宣布推出折扣胰岛素笔wboi.org
- 63药企同意下调部分药品在华售价zaobao.com.sg
- 64礼来公布2019年第三季度业绩prnewswire.com
- 65Eli Lilly宣布关闭Erl Wood研究中心并可能裁员basingstokegazette.co.uk
- 66礼来入驻1药网线上糖尿病平台 疫情之下药企与电商合作加速finance.sina.com.cn
- 67Amazon reports higher sales as US companies file quarterly results | EconoTimeseconotimes.com
- 68Big Pharma Eli Lilly Cuts Insulin Prices By 70%, Helping Access For Diabetes Sufferersmoguldom.com
- 69Drug maker Eli Lilly cuts insulin price by nearly 70%, promises $35 out-of-pocket capwxyz.com
- 70Drugmaker Eli Lilly Announces 70% Price Drop In Its 'Most Commonly Prescribed Insulins'laist.com
- 71Eli Lilly Acquires Sigilon Therapeutics to Develop Long-Term Solution for Diabetes | EconoTimeseconotimes.com
- 72Eli Lilly announces 70% cut to US insulin prices while also capping out-of-pocket costs - PMLiVEpmlive.com
- 73Eli Lilly announces price cuts for some insulins later this yearnpr.org
- 74Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China - Reutersnews.google.com
- 75Eli Lilly Reduces Price On Generic Insulin A Second Timewbaa.org
- 76Eli Lilly sues businesses selling knockoff versions of Mounjarospokesman.com
- 77Eli Lilly Sues Clinics Over Unauthorized Mounjaro Drug Salefinanznachrichten.de
- 78Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Salesfinanznachrichten.de
- 79Eli Lilly sues six firms over illegal retatrutide salesbignewsnetwork.com
- 80FDA Approves Eli Lilly's Antibody Combo Treatmentscrippsnews.com
- 81FDA Approves New Treatment for Hair Loss From Severe Alopecia Areataeverydayhealth.com
- 82FDA approves Zepbound as a treatment for obesitykfyrtv.com
- 83Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales - PMLiVEpmlive.com
- 84Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentumprnewswire.com
- 85Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potentialprnewswire.com
- 86Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patientsprnewswire.com
- 87Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidanceprnewswire.com
- 88Lilly sues companies selling unapproved obesity drug retatrutidebruneinews.net
- 89Lilly sues medical spas, wellness centers, compounding pharmacies over diabetes drug knockoffswishtv.com
- 90Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutidecnbc.com
- 91Nektar Sues Eli Lilly, Claiming the Big Pharma Breached Contract to Favor Another Drug - MedCity Newsmedcitynews.com
- 92Ozempic and Mounjaro makers sued by patient alleging ‘severe gastrointestinal issues'nbcsandiego.com
- 93ROUNDUP: Lilly Cuts FY22 Earnings Outlook Againfinanznachrichten.de
- 94Wellness Wednesday: Drug maker Eli Lilly announces price cap on commonly prescribed insulinwosu.org
Cite this profile: Cite the canonical profile. /brandpedia/eli-lilly · Editorial policy · How profiles are compiled